C([O-])([O-])=O.[K+].[K+].[Br:7][C:8]1[C:16]2[C:11](=[N:12][CH:13]=[C:14]([NH:17][C:18](=[O:40])[C:19]3[C:24]([F:25])=[CH:23][CH:22]=[C:21]([N:26](S(CCC)(=O)=O)[S:27]([CH2:30][CH2:31][CH3:32])(=[O:29])=[O:28])[C:20]=3[F:39])[CH:15]=2)[N:10](S(C2C=CC(C)=CC=2)(=O)=O)[N:9]=1>CO.O>[Br:7][C:8]1[C:16]2[C:11](=[N:12][CH:13]=[C:14]([NH:17][C:18](=[O:40])[C:19]3[C:24]([F:25])=[CH:23][CH:22]=[C:21]([NH:26][S:27]([CH2:30][CH2:31][CH3:32])(=[O:29])=[O:28])[C:20]=3[F:39])[CH:15]=2)[NH:10][N:9]=1K2CO3 (0.151 g, 1.09 mmol) was added to a solution of N-(3-bromo-1-tosyl-1H-pyrazolo[3,4-b]pyridin-5-yl)-2,6-difluoro-3-(N-(propylsulfonyl)propylsulfonamido)benzamide (0.100 g, 0.136 mmol) in MeOH/H2O (4:1, 10 mL), and the reaction mixture was heated to 60° C. for 1 hour. The reaction mixture was cooled to room temperature and concentrated. The resulting residue was taken up in ethyl acetate (100 mL) and washed with water (50 mL). The crude product was purified by column chromatography, eluting with hexanes/ethyl acetate (2:1), hexanes/ethyl acetate (1:1) to give N-(3-bromo-1H-pyrazolo[3,4-b]pyridin-5-yl)-2,6-difluoro-3-(propylsulfonamido)benzamide (0.024 g, 37%, 2 steps) as a solid. 1H NMR (400 MHz, CD3OD) δ 8.7 (s, 1H), 8.5 (s, 1H), 7.7 (m, 1H), 7.1 (m, 1H), 3.1 (m, 2H), 1.9 (m, 2H), 1.1 (t, J=7.6 Hz, 3H); m/z (APCI-neg) M−1=472.2, 474.2.